Skip to content
MomMetabolicEVIDENCE-FIRST METABOLIC HEALTH
Menu
Grade C

Jyra Health review

Written by Elena Voss, Metabolic Health Editor

Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Prices and terms come from the company's own published pages. This is background reading, not medical advice.

Semaglutide: $169/mo monthly ($99/mo on a 3-month plan); tirzepatide: $229/mo monthly ($133/mo on a 3-month plan). The lower $99 and $133 figures require $297 or $399 paid for three months, with the same price at every dose.

$169/mo
Consult Medication Shipping
See plans at Jyra Health
  • Confirm HSA / FSA coverage
  • Public information reviewed
  • Confirm your total cost
Compare alternatives ↓

Jyra Health at a glance

Semaglutide
$169/mo monthly ($99/mo on a 3-month plan)
Tirzepatide
$229/mo monthly ($133/mo on a 3-month plan)
Coverage
All 50 states
Brand-name
Compounded only

How we scored Jyra Health

Every factor comes from Jyra Health's own published pricing, disclosures and oversight, and the six combine into the 49/100 Metabolic-Fit Score on our weighted six-factor framework. Commissions don't change a provider's score.

Postpartum & breastfeeding guidance30/100 · Weak

No postpartum or breastfeeding framing — a generic weight program.

PCOS & hormonal fit35/100 · Weak

Thin on the hormonal picture that drives many mothers' weight.

Clinical oversight & labs48/100 · Weak

Oversight and lab support fall short of the best on our list — the review below says exactly where.

True monthly cost85/100 · Strong

Fair pricing once you read past any teaser or plan structure.

Ongoing support55/100 · Weak

Support is thin once the prescription ships.

Cancellation fairness55/100 · Weak

Exit terms are the weak point: lock-in, notice periods, or a cancellation you have to chase.

How we checked this review

Semaglutide: $169/mo monthly ($99/mo on a 3-month plan); tirzepatide: $229/mo monthly ($133/mo on a 3-month plan). The lower $99 and $133 figures require $297 or $399 paid for three months, with the same price at every dose.

Before you sign up

What Jyra Health's public site and signup page show before you hand over any details.

Worth knowing

  • The homepage lists both molecules with real starting prices directly, no intake required to see the numbers
  • The site states 'no hidden fees, no monthly membership,' and describes a three-step process: assessment, free provider review, then delivery
  • Claims '600+ treated this month' as a recent-volume signal
  • Both core GLP-1 starting prices are among the lowest disclosed we've seen — worth confirming the real ongoing rate carefully
  • Free provider review, fast online approval, and free express delivery are all stated as included
  • No mention anywhere of pregnancy, breastfeeding, postpartum care, or PCOS

Pricing

MedicationPricePlan
Compounded semaglutide$169One-month planNo dose upcharge or renewal increase.
Compounded semaglutide$993-month prepaid plan$297 total upfront.
Compounded tirzepatide$229One-month planNo dose upcharge or renewal increase.
Compounded tirzepatide$1333-month prepaid plan$399 total upfront.

Swipe the table to see plan details →

Many HSA and FSA plans cover GLP-1 telehealth — check yours. These figures are what Jyra Health's own site disclosed at last review; this market re-prices often, so confirm the current number at the source.

What we like

  • Free provider review, fast online approval, and free express delivery all stated as included
  • Semaglutide: $169/mo monthly ($99/mo on a 3-month plan); tirzepatide: $229/mo monthly ($133/mo on a 3-month plan).

The caveats

  • No mention anywhere of pregnancy, breastfeeding, postpartum care, or PCOS
  • No named compounding pharmacy or medical director found on the site
  • No brand-name (FDA-approved) option and no oral form
  • The lower $99 and $133 figures require $297 or $399 paid for three months, with the same price at every dose.

One month and three months have different payment amounts

Jyra Health lists semaglutide at $169 monthly and tirzepatide at $229. The lower advertised equivalents of $99 and $133 come from three-month purchases of $297 and $399. Someone who wants one month before deciding whether to continue should therefore use $169 or $229 for comparison, rather than assume that the quarterly average can be paid separately each month. Both the molecule and the commitment need to stay attached to the selected price.

Jyra says pricing remains the same at every dose without a renewal increase. That can help a patient distinguish the ongoing budget from a program whose rate rises with prescribed amount. It does not make the quarterly purchase refundable or eliminate the need to understand what happens if the treatment plan changes. Ask how the supply is delivered, what amount is charged at renewal and whether a pause or re-enrollment affects the stated rate. A price promise is most useful when its practical limits are clear before a larger payment.

A simple injectable menu, with the prescriber still responsible

The program offers compounded injectable semaglutide and tirzepatide without an oral or approved-brand alternative in the available menu. That makes product preference an early decision point. Someone seeking an FDA-approved finished medicine or avoiding injections should not expect the quarterly discount to solve a mismatch in the type of treatment. A compounded preparation should be discussed as the actual product supplied, without transferring labeling or outcomes from a brand containing the same active ingredient.

Free provider review, online approval and express delivery are advertised inclusions. They do not guarantee that an application leads to a requested prescription or that the medication arrives on a specific day after applying. Ask whether the assessment requires a live conversation in the patient's state, how clarification requests work and which professional manages the prescription afterward. Fast enrollment may be convenient, but ongoing access becomes more important when a question arises between shipments or the clinician recommends changing the plan.

A low quarterly equivalent leaves service details to confirm

Jyra claims coverage across fifty states, while the available public information does not identify a medical director or named compounding pharmacy. Confirm the actual practice and dispenser for the intended order, along with eligibility in the consultation and delivery locations. A nationwide statement does not identify who takes responsibility for a particular prescription. Ask where labeling or shipping questions go and how those contacts differ from clinical follow-up. Those answers matter when transferring care or purchasing a longer supply from an unfamiliar service.

The company also offers little written guidance on pregnancy, breastfeeding, postpartum recovery or PCOS. Relevant history and coordination with existing clinicians need direct discussion rather than an assumption of maternal specialization. Before choosing a quarterly plan, obtain the cancellation procedure, processing cutoff and treatment of unused or unshipped supply in writing. Jyra's current monthly-versus-quarterly distinction is readable and its stated flat-dose policy can simplify budgeting. The best fit is someone comfortable with the actual injectable prescription and term, with the clinical team, pharmacy and financial exit identified before relying on the lower equivalent. A lower quarterly average is useful only if the patient understands what happens to that purchase when care changes.

The bottom line for mothers

Best for: Someone comfortable with the stated plan commitment who confirms the full prescribed treatment cost before paying.

Alternatives to Jyra Health

These are partners — we may be paid if you sign up through these links. The full list has every provider we cover, partner or not.

  • CoreAge RxFeatured partner

    CoreAge's officially linked public offer advertises compounded semaglutide at $79/month and tirzepatide at $129/month across doses, with care and overnight shipping included. It describes one-time purchases without a required subscription. Main navigation still shows semaglutide from $99; confirm your prescription quantity and total, and read the refund limits before paying.

    Visit CoreAge Rx
  • $165/mo semaglutide and $214/mo tirzepatide month to month, dropping to $97 and $177 on a 12-month plan — with a genuinely itemized exclusion list that explicitly screens out pregnancy, planned pregnancy, and breastfeeding rather than staying silent on it.

    Visit HealthRX
  • A complete plan table and real nationwide coverage, undercut by a homepage that strikes the same product through from two different “regular” prices.

    Visit bmiMD

Providers like Jyra Health

Keep comparing Jyra Health

Jyra Health, answered

How much does Jyra Health cost?
At last review, Jyra Health's lowest ongoing compounded rate was about $169/mo — $169/mo monthly ($99/mo on a 3-month plan) for semaglutide, $229/mo monthly ($133/mo on a 3-month plan) for tirzepatide. This market re-prices often, so check the current all-in figure at the source before committing.
Is Jyra Health safe to use while breastfeeding?
No GLP-1 is established as safe in pregnancy. Nursing is less clear-cut. The Wegovy injection, Ozempic, Zepbound and Mounjaro labels have little or no breast-milk data and ask you and your clinician to weigh the benefits of breastfeeding against how much you need the drug. Compounded versions carry no label of their own, which puts more of that judgment on your prescriber. Jyra Health is not an exception to any of that — settle the timing with your own clinician.
Does Jyra Health offer both semaglutide and tirzepatide?
Yes — Jyra Health offers both molecules. Tirzepatide's dual GIP/GLP-1 action is often preferred where insulin resistance drives weight, which matters for PCOS and after gestational diabetes.
How does Jyra Health score for mothers?
Jyra Health scores 49/100 on our Metabolic-Fit Score, a weighted read of six things mothers actually have to care about. CoreAge Rx, a featured partner, is worth a side-by-side look.

Pricing, states and verification reflect Jyra Health's public disclosures at last review; the Metabolic-Fit Score is our editorial judgment per the published methodology. This is background reading, not medical advice — GLP-1 medications are not established as safe in pregnancy or breastfeeding. See our medical disclaimer and how we're funded.

← Back to all providers